9.90 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||6.55 x 1000|
|Ask||11.10 x 1000|
|Day's Range||9.45 - 10.04|
|52 Week Range||4.80 - 12.95|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you own shares in Minerva Neurosciences Inc (NASDAQ:NERV) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Minerva Neurosciences shares have climbed 32 percent since the beginning of the year. The stock has increased 13 percent ...
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 32 cents. Minerva Neurosciences shares have risen 14 percent since the beginning of the year. The stock has fallen nearly ...
The Waltham, Massachusetts-based company said it had net income of less than 1 cent on a per-share basis. Losses, adjusted for pretax gains, were 24 cents per share. For the year, the company reported ...
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.